Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK6 | Q16659 | 12/20 | 0.63 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | EIF2AK4 | Q9P2K8 | 2/20 | 0.41 |
| ▸ | HPGDS | O60760 | 3/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16012730 | 0.83 | MAPK6 (0.74) | MAPK6GSK3AGSK3BEIF2AK4HPGDS | |
| SCHEMBL18830294 | 0.81 | MAPK6 (0.89) | MAPK6GSK3AGSK3BEIF2AK4 | |
| SCHEMBL16012546 | 0.81 | MAPK6 (0.89) | MAPK6GSK3AGSK3BEIF2AK4 | |
| SCHEMBL18830228 | 0.81 | MAPK6 (0.61) | MAPK6GSK3AGSK3BEIF2AK4 | |
| SCHEMBL18830211 | 0.80 | MAPK6 (0.60) | MAPK6GSK3AGSK3BEIF2AK4 | |
| SCHEMBL18830258 | 0.78 | MAPK6 (0.66) | MAPK6GSK3AGSK3BEIF2AK4 | |
| SCHEMBL16012179 | 0.78 | MAPK6 (0.89) | MAPK6GSK3AGSK3BEIF2AK4 | |
| SCHEMBL16012470 | 0.78 | MAPK6 (0.89) | MAPK6GSK3AGSK3BEIF2AK4 | |
| SCHEMBL18830134 | 0.78 | MAPK6 (0.89) | MAPK6GSK3AGSK3BEIF2AK4 | |
| SCHEMBL16022034 | 0.78 | MAPK6 (0.89) | MAPK6GSK3AGSK3BEIF2AK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964649-B1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2017-05-10 | — | — | EP | disclosed |